
Atrium Therapeutics (RNA) Stock
Early stage biotech developing targeted treatments for muscle diseases. Here's the price, business snapshot, and what's worth knowing about Atrium Therapeutics in November 2026.
Avidity Biosciences (RNA) is a clinical-stage biotechnology company developing antibody–oligonucleotide conjugates (AOCs) to deliver RNA-targeted medicines, primarily for neuromuscular diseases such as Duchenne muscular dystrophy and myotonic dystrophy. With a market capitalisation of around US$6.66bn, the company is valued on the promise of its novel delivery platform and early clinical data rather than steady revenues. Investors should understand Avidity’s profile: research and development progress, trial readouts, regulatory milestones and cash runway can move the share price materially. Biotech investing carries binary risks — positive trial results can drive gains, while setbacks or safety concerns can lead to sharp declines. The company may require additional funding over time. This summary is educational and not personalised advice; suitability depends on your circumstances and risk tolerance, and it is sensible to consider independent financial advice before investing.
Atrium Therapeutics (RNA) Stock Forecast
Analyst price target, next 12 months
$72.62
+960.1% vs today's $6.85
Price range over the last 12 months
Close to its 12-month low
Analysts covering Atrium Therapeutics have a consensus 12-month target of $72.62, above the current price of $6.85.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 18 Nov 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Six-Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend holding ATRIUM THERAPEUTICS' stock with a target price of $72.62, indicating potential growth.
Financial Health
Atrium Therapeutics is performing well with strong revenue and cash flow, indicating good financial health.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Novel delivery platform
Avidity’s AOC technology aims to improve tissue delivery of RNA medicines, a potential differentiator — though clinical proof is still evolving.
Data-driven catalysts
Clinical trial readouts and regulatory milestones can be major share-price catalysts; outcomes may be binary and cause volatility.
Rare-disease focus
Targeting neuromuscular rare diseases offers high unmet need and potential premium pricing, but small patient populations and regulatory hurdles add risk.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.